Healx

October 1st is #CACNA1CAwareness Day, and we're joining Timothy Syndrome Alliance to help spread awareness for CACNA1C-related diseases and advocate for more research and treatment options for those affected by these diseases.

Our Chief Collaboration Officer Bruce Bloom will be speaking at the Beacon for Rare Diseases Cambridge Rare Disease Showcase on 2nd October to discuss #AI development of #raredisease therapies. We're looking forward to sponsoring and speaking at this event which brings together industry experts, patient groups, and healthcare providers to share ideas, progress and achievements in rare diseases. Learn more about #RareShowcase24 here: https://lnkd.in/eHw5xhGd

At Healx, we are true believers that every rare disease patient deserves treatment. That's why our first company value is "care for rare". Every day, we strive to turn this value into action by leveraging cutting-edge #AI technology to accelerate the discovery of life-changing therapies for the #raredisease community. Dive into this company value below, and learn more about who we are here: https://healx.ai/about/ 

We're thrilled to have received the Life Science AI award at the 34th #BusinessWeeklyAwards! This award reflects our team's dedication to revolutionizing #raredisease treatment through cutting-edge AI-driven drug discovery. Thank you to our team members and partners who helped make this possible, and to BusinessWeekly newspaper for a wonderful evening and for recognizing our mission to make a positive difference to rare disease patients and their families. L-R: Guest speaker Dr Hermann Hauser, Tim Guilliams, David Brown and Barnaby Perks, CEO of sponsoring company St John's Innovation Centre Ltd Photo: Phil Mynott - www.philmynottphoto.co.uk

Our Scientific Associate Director Phil Brownjohn will be giving two poster presentations at Cilia2024, the world’s largest scientific meeting for cilia and flagella research. We're excited to share our research at the event and learn more about the recent developments in #cilia and #ciliopathy research. Learn more about the event here: https://cilia2024.ie/

The future of #drugdiscovery is here, and it's powered by AI. At Healx, we utilize #AI to develop new treatments for #rarediseases. Not only can the use of AI help reduce costs and timelines, it can open the doors for greater scalability, thus reaching a broader patient population. Read more about the power of AI in #biotech in this article from The Times.

I just read a truly inspiring post from my dear friend, Dr Jack Kreindler, describing the parallels between Michelangelo’s ‘David’ and the battles we face in Biotech. In the fight against rare diseases, it's even more the case. We often feel like David going up against Goliath. The challenges are immense, and the odds can seem overwhelming. But as Michelangelo’s ‘David’ teaches us, true innovation often comes from the most unexpected places. At Healx, we’re on a relentless quest to discover new medicines for those who need them most—patients with rare diseases who have long been overlooked. 95% of rare diseases don't have an approved treatment today. Our weapon of choice in this battle? AI-driven drug discovery. Just as David used his slingshot with precision, we use advanced AI to pinpoint and develop treatments with unparalleled accuracy, targeting the very roots of complex diseases. Rare diseases represent one of the greatest unmet needs in medicine, with over 300 million patients around the world still waiting for effective treatments. But with every breakthrough, every step forward, we’re proving that even the smallest, most focused efforts can make a world of difference. Together, we’re carving out a new path in healthcare—one that stands tall against the giants of the industry, not by sheer size or force, but by innovation, passion, and a commitment to those who have been forgotten for too long. #RareDiseases #AI #Biotech #Innovation #DavidVsGoliath #DrJack

Neurofibromatosis type 1 (#NF1) is a rare genetic disorder associated with predisposition to develop multiple benign and malignant tumors along the nerves. By combining generative #AI technology with deep drug discovery and development expertise, we are aiming to accelerate the pace, increase the scale and improve the chance of success of treatment development for patients. Our Head of Neurofibromatosis Therapy Development Simone Manso talks more about our approach and the hope we have for more treatment options below.

We're incredibly excited for the opportunities that lie ahead following today's news. Learn more about our mission and our AI approach for finding treatments for #rarediseases, including #NF1, in this feature with BiotechTV below.

It's truly a pivotal time for our team. We're proud to announce two significant updates: • We raised $47 million in a Series C financing round. • The U.S. FDA has cleared our IND application to advance HLX-1502 in Phase 2 clinical trial in Neurofibromatosis Type 1 (NF1). The Series C financing was co-led by R42 Group and Atomico Balderton, Jonathan Milner, Global Brain, btov, Ayana Capital, o2h and VU Venture Partners. Proceeds of the financing will be used to advance our rare oncology, renal and neurodevelopmental disorders pipeline which includes our lead program targeting #NF1, a rare genetic condition that causes tumours to grow along the nerves. With this IND clearance, we plan to initiate the Phase 2 clinical trial for HLX-1502 by the end of 2024. Read more about today's announcements here: https://lnkd.in/eJmXb5Wy